Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

French Innovative Leukemia Organization (F.I.L.O.).
Sponsor

French Innovative Leukemia Organization (F.I.L.O.).

France 2 Boulevard Tonnelle, 37000 Tours, France

About the sponsor

The sponsor supports research in acute myeloid leukemia across both treatment-naive and relapsed settings, with interest in molecularly defined disease such as FLT3-mutated AML and IDH1-mutated AML. Its portfolio also includes work in blastic plasmacytoid dendritic cell neoplasms, reflecting a focus on aggressive hematologic malignancies.

  • FLT3-mutated acute myeloid leukemia
  • IDH1-mutated acute myeloid leukemia
  • Blastic plasmacytoid dendritic cell neoplasms
  • Post-remission therapy in AML

These studies place emphasis on disease control in older adults and on biologically targeted approaches within myeloid cancer care.

About Specializations

French Innovative Leukemia Organization (F.I.L.O.). runs clinical trials in conditions such as Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Blastic plasmacytoid dendritic cell neoplasia, Richter's syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

7 clinical trials

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Richter's syndrome

Recruiting

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Not yet recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Acute myeloid leukaemia

Not yet recruiting

A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Chronic lymphocytic leukaemia

Not yet recruiting

Study of pirtobrutinib combined with immuno-chemotherapy for previously untreated patients with symptomatic chronic lymphocytic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Acute myeloid leukaemia

Not recruiting

Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Chronic lymphocytic leukaemia+1

Not recruiting

Study on Stopping and Restarting Acalabrutinib in Elderly Patients with Untreated Chronic Lymphocytic Leukemia (CLL)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Acalabrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.